Maxxis™ 300
Description:The Ma
xxis™ 300 is a healthcare bed system which helps provide comfort and safety for individuals in the home care setting INDICATIONS: Patients weighing up to 600 lbs.(or combined weight of 2) Healthcare frame accommodating one or two individuals, depending on frame size selected CONTRAINDICATIONS: Total weight in excess of 600 lbs. (including accessories)<b...
Company:Kinetic Concepts, Inc.
Maxxis™ 400
Description:The Ma
xxis™ 400 is a bariatric bed system which helps provide comfort and safety for individuals in the home care setting INDICATIONS: Patients weighing up to 1000 lbs. (or combined weight of 2) Healthcare frame accommodating one or two individuals, depending on frame size selected CONTRAINDICATION: Total weight in excess of 1000 lbs. (including accessories...
Company:Kinetic Concepts, Inc.
AirMaxxis™
Description:KCIs AirMa
xxis™ is a pressure relief mattress overlay designed specifically for AirMa
xxis frame. It provides low air loss therapy for those patient with skin breakdown or at risk for skin breakdown. INDICATIONS: Patients whose body weight and size pose a significant risk or care management issue to the patient or staff during the performance of routine nursing care...
Company:Kinetic Concepts, Inc.
Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis
RIDGEFIELD, Conn., July 11, 2007 /PRNewswire/ -- Phase 3 resultsfrom the RE-NOVATE(TM) trial demonstrated that oral dabigatranetexilate once daily, administered for an average of 33 days, wasnon-inferior to enoxaparin, also administered for an average of 33days, in preventing venous thromboembolism (VTE) and all-causemortality after total hip replacement surgery. In this trial, therate o...
Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis
HORSHAM, Pa.--(BUSINESS WIRE)--Jul 11, 2007 - Neose Technologies,Inc. (Nasdaq GM:NTEC) today announced that two poster presentationswere presented with its collaborative partner, Novo Nordisk A/S,relating to GlycoPEGylated recombinant Factor VIIa at the
XXIstCongress of the International Society on Thrombosis and Haemostasisin Geneva, Switzerland. The data presented demonstrates thatGlycoPE...
Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
SAN FRANCISCO, July 10, 2007 /PRNewswire/ -- PortolaPharmaceuticals, Inc. announced positive Phase II data on its leadcompound, PRT054021, an oral Factor Xa inhibitor, today at the
XXICongress of the International Society on Thrombosis and Haemostasis(ISTH) in Geneva, Switzerland. The EXPERT trial showed thatPRT054021 was safe, effective, and well tolerated for theprevention of venous th...
Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst
Congress of the International Society on Thrombosis and Haemostasis
SAN CARLOS, Calif., July 5 /PRNewswire-FirstCall/ -- Nuvelo,Inc. (Nasdaq: NUVO) today announced that data from the ANTHEM(Anticoagulation with rNAPc2 To Help Eliminate MACE)/TIMI 32 Phase2 trial looking at recombinant nematode anticoagulant protein c2(rNAPc2) in patients with acute coronary syndromes (ACS),preclinical data evaluating rNAPc2 in mouse models of colorectalcancer, and precli...
Portola Pharmaceuticals Announces Positive Phase II EXPERT Results
and Additional Oral and Poster Presentations at the XXI Congress of
the International Society on Thrombosis and Haemostasis (ISTH)
SOUTH SAN FRANCISCO, July 02, 2007 /PRNewswire/ -- PortolaPharmaceuticals, Inc. announced today that it will present clinicaland preclinical data on its oral Factor Xa inhibitor and on itsintravenous and oral ADP receptor antagonist at the
XXI Congress ofthe International Society of Thrombosis and Haemostasis (ISTH) inGeneva, Switzerland on July 6 through July 12, 2007. The EXPERT...